Search
Filters
Clear All
  • 11
  • 17
  • 123

Phase

  • 4
  • 9
  • 19
  • 1
  • 20
  • 94
  • 144
  • 43

Found 151 Neoplasms trials

A listing of Neoplasms medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

A Phase 1a/1b Study of the PI3Ka: RAS Breaker BBO-10203 in Subjects with Advanced Solid Tumors (The BREAKER-101 Trial)

M
Mateusz Opyrchal, MD, PhD
18 years - 100 years
All genders
Phase 1/2
What is the purpose of this study?Phase 1a Dose Escalation/Cohort Expansion BBO-10203 Monotherapy Primary: To evaluate the safety and tolerability of BBO-10203, an inhibitor of the PI3Kα:RAS interaction, in subjects with locally advanced unresectable or metastatic (ie, advanced) HER2-positive BC; HR-positive, HER2-negative BC; KRAS mutant NSCLC; and KRAS mutant CRC. Secondary: To evaluate …
Learn More

Phase II Randomized Double-Blind Study of mFOLFIRINOX plus Ramucirumab versus mFOLFIRINOX plus placebo in Advanced Pancreatic Cancer Patients HCRN GI14-198

18 years - 100 years
All genders
The purpose of this study is to find out what effects, good and/or bad, there are to adding the drug ramucirumab (RAM) to the usual chemotherapy regimen.
Learn More

A Dose Escalation Study of Intensity Modulated Total Marrow Irradiation (IMRT-TMI) with Fludarabine as a Myeloablative Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Relapsed and Refractory Hematologic Malignancies

N
Naoyuki Saito, MD
18 years - 65 years
All genders
The purposes of this study are to: (1) find the most effective dose of a new type of radiation therapy called total marrow irradiation (TMI) that will be given with the conditioning chemotherapy, fludarabine, to prepare patients for allogeneic hematopoietic stem cell transplantation (Allo-HSCT); and (2) see if utilization of …
Learn More

A Randomized Phase II Study of Anti-PD1 Antibody [MK-3475 (Pembrolizumab)] Alone Versus Anti-PD1 Antibody Plus Stereotactic Body Radiation Therapy in Advanced Merkel Cell Carcinoma

A
Ahmad Al-Hader, MD
18 years - 100 years
All genders
This randomized phase II trial studies how well pembrolizumab with or without stereotactic body radiation therapy works in treating patients with merkel cell cancer that has spread to other places in the body.
Learn More

A Phase II Trial of Atezolizumab plus Chemotherapy after Progression on Single Agent PD-1 or PD-L1 Inhibitor in Cisplatin-ineligible Patients with Advanced Urothelial Carcinoma

N
Nabil Adra, MD
18 years - 100 years
All genders
The purpose of this study is to compare any good and bad effects of using Atezolizumab along with the usual chemotherapy after progression with PD-1 or PD-L1 Inhibitor for individuals with urothelial carcinoma (cancer of the urinary tract).
Learn More

A Pilot Study Evaluating a Novel Biodynamic Imaging (BDI) Method in Predicating Response to Chemotherapy in Locoregional Esophageal Cancer

S
Shadia Jalal, MD
18 years - 100 years
All genders
Researchers would like to determine if a new imaging technique called Biodynamic Imagining (BDI) is appropriate for clinical use in the treatment of esophageal cancer. The purpose of this study is to determine if the tumor tissue can be collected, transported and successfully processed using BDI technology.
Learn More

A Phase 2 Multicenter Study to Assess the Efficacy and Safety of Autologous Tumor Infiltrating Lymphocytes (LN-144) for Treatment of Patients With Metastatic Melanoma

T
Theodore Logan, MD
18 years - 70 years
All genders
Prospective, interventional multicenter study evaluating adoptive cell therapy (ACT) with Lifileucel infusion (LN-144) followed by interleukin 2 (IL-2) after a nonmyeloablative lymphodepletion (NMA-LD) preparative regimen.
Learn More

A first-in-human, Phase I Study to Evaluate the Safety of TTX-080, an HLA-G Antagonist, in Subjects with Advanced Solid Tumors

G
Greg Durm, MD
18 years - 100 years
All genders
Phase 1
To assess the safety and tolerability of TTX-080
Learn More

Pilot Study of Respiratory-gated Stereotactic Body Radiation Therapy for Borderline Resectable Unresectable or Recurrent/Residual Adenocarcinoma of the Pancreas or Periampullary Region

R
Ryan Rhome, MD
18 years - 100 years
All genders
This is a single center, single arm unblinded prospective study of the safety of pancreatic stereotactic body radiation therapy (SBRT) in patients with unresectable, borderline resectable, or recurrent pancreatic/periampullary cancers who have previously undergone treatment with chemotherapy, surgery, photodynamic therapy, conventionally fractionated radiation treatment, or any combination of these therapies.
Learn More

A Phase I First-in-Human Multicenter Randomized Double-Blinded Placebo- Controlled Study of the Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Cancer Survivors with Anthracycline-Induced Cardiomyopathy

M
Michael Murphy, MD
18 years - 79 years
All genders
The primary purpose of this study is to examine the safety and feasibility of delivering allogeneic human mesenchymal stem cells (allo-MSCs) by transendocardial injection to cancer survivors with left ventricular (LV) dysfunction secondary to anthracycline-induced cardiomyopathy (AIC).
Learn More
111 - 120 of 151